Health Canada halts new prescriptions of TAVNEOS over trial-data integrity concerns

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

What happened

Health Canada issued a risk communication on July 7, 2026, directing physicians across Canada to stop initiating treatment with TAVNEOS (avacopan, sold in Canada under the brand name TAVNEOS by Otsuka Canada) while the regulator assesses whether the drug's benefits still outweigh its risks. The concern centres on the Phase 3 ADVOCATE trial, the primary study used to support Health Canada's April 2022 authorization of the drug. According to Health Canada, new information has raised "significant concerns" about how data from that trial was handled before authorization, creating uncertainty about the reliability of the evidence for the drug's effectiveness.

For Canadians living with ANCA-associated vasculitis (anti-neutrophil cytoplasmic autoantibody-associated vasculitis), a group of rare autoimmune diseases that cause dangerous inflammation of blood vessels, this is a direct and immediate concern. If you or someone you care for is currently prescribed TAVNEOS, Health Canada's guidance is clear: do not stop the medication without first speaking to your physician. The regulator has not suspended the drug's market authorization outright; it has paused new prescriptions while its review proceeds.

What this means in Canada

TAVNEOS received Health Canada authorization in April 2022 for adults with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis. It is approved as an add-on to standard therapy that typically includes glucocorticoids (corticosteroids), and is not approved for use on its own.

The drug is also FDA-approved in the United States (US); Health Canada's review is proceeding independently, though both regulators are responding to the same underlying data-integrity questions about the ADVOCATE trial.

Provincial drug coverage for TAVNEOS varies. Because ANCA-associated vasculitis is rare, coverage decisions have generally been made through exceptional-access or special-authorization pathways rather than routine formulary listing. Patients in Ontario may have accessed the drug through the Exceptional Access Program; in Quebec, through the RAMQ's Liste des médicaments with a special authorization; in British Columbia through PharmaCare's Special Authority process; and in Alberta through the Alberta Rare Disease Drug Program under AHCIP. Patients with private insurance may have separate coverage. If you are currently receiving TAVNEOS through any of these channels, Health Canada's advisory does not automatically cancel your existing prescription, but your specialist will need to reassess whether continuing is appropriate.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has no direct mandate over vasculitis pharmacotherapy, and no Canadian specialty society has yet issued a formal position statement in response to this specific advisory. The Canadian Vasculitis Research Network (CanVasc), which publishes recommendations for ANCA-associated vasculitis management in Canada, has not yet released updated guidance as of the date of this article.

Why this matters

The trigger for Health Canada's review was not a new safety signal or a report of patient harm. It was a data-integrity problem with the ADVOCATE trial itself. On June 29, 2026, the New England Journal of Medicine retracted its publication of the ADVOCATE trial, citing concerns about how the trial data was handled before the drug was authorized. The NEJM retraction is significant: the ADVOCATE trial was the single pivotal study underpinning regulatory approval in both Canada and the United States. Without a reliable published record of that trial, the evidentiary foundation for the drug's effectiveness is now in question.

This is a different category of concern from a typical safety recall. Health Canada is not saying TAVNEOS caused unexpected harm. It is saying it cannot currently confirm that the drug works as well as the original trial claimed, because the data supporting that claim may not be trustworthy. The regulator is now reassessing the drug's overall benefit-risk profile.

Health Canada is notifying physicians through its MedEffect system and the Healthy Canadians recalls and safety alerts database. It is also asking both clinicians and patients to report any serious or unexpected adverse reactions associated with TAVNEOS through MedEffect Canada.

What Canadian patients should know

ANCA-associated vasculitis is a serious, potentially organ- and life-threatening condition. Stopping immunosuppressive or anti-inflammatory therapy abruptly without medical supervision carries real risks, including disease flare. Health Canada has been explicit: patients currently on TAVNEOS should not discontinue on their own. The right step is to contact your rheumatologist, nephrologist, or specialist and discuss whether continuing, switching to an alternative, or tapering is appropriate for your specific situation.

Alternative treatments for ANCA-associated vasculitis exist and remain unaffected by this advisory. Standard regimens include rituximab (sold in Canada as Rituxan) and cyclophosphamide combined with glucocorticoids, which were the comparator arms in the ADVOCATE trial itself. Your specialist can advise on whether a transition to one of these options makes sense while Health Canada's review is underway.

Because TAVNEOS is a specialty drug for a rare disease, it is not typically prescribed through general telehealth platforms. Canadian virtual-care services such as Felix, Cleo, Maple, or Telus Health do not prescribe TAVNEOS; this drug is managed by specialists in rheumatology, nephrology, or respirology. Science & Humans (scienceandhumans.com) similarly focuses on hormone optimization and metabolic health, not vasculitis pharmacotherapy. If you received TAVNEOS through a hospital or specialist clinic, that is where your follow-up conversation should happen.

Provincial differences matter here. Patients in provinces with active exceptional-access files may find that their provincial drug program contacts them directly if the authorization status of TAVNEOS changes. Watch for communications from your provincial health authority and keep your specialist's contact information current.

Limitations and open questions

Health Canada has not yet concluded its review. The regulator has not stated a timeline for when it will complete its assessment or announce a final decision on TAVNEOS's market authorization status. It is possible the review will result in the authorization being maintained with updated labelling, suspended, or revoked entirely. None of those outcomes has been determined as of July 9, 2026.

The nature of the data-integrity concerns in the ADVOCATE trial has not been fully disclosed publicly. Health Canada's risk communication describes "significant concerns" about how data was handled before authorization, but the specific nature of those concerns, whether they involve data manipulation, transcription errors, protocol deviations, or something else, has not been detailed by the regulator or the NEJM in its retraction notice.

It is also not yet clear whether the US Food and Drug Administration (FDA) will take parallel action on its own approval of avacopan. Health Canada's review is independent, and the two agencies may reach different conclusions or move at different speeds.

Canadian patients and clinicians can monitor updates through the Health Canada recalls and safety alerts database and the MedEffect Canada system. No Canadian specialty society has issued updated clinical guidance as of this writing.